Compare
Johnson & Johnson vs Pacira BioSciences (JNJ vs PCRX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Johnson & Johnson (JNJ) returned +48.5% and Pacira BioSciences (PCRX) +66.7%; so far this year the figures are +33.5% and +40.8%.
Johnson & Johnson is the larger company by market value, about 455.4 times the size of Pacira BioSciences.
On trailing earnings, JNJ trades at 41.9 times and PCRX at 39.2 times.
Revenue grew +7.8% at JNJ and +3.7% at PCRX over the last year.
JNJ yields 1.91%. PCRX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| JNJ | PCRX | |
|---|---|---|
| Price | $276.22 | $36.43 |
| 1-day | +1.43% | +0.03% |
| YTD | +33.47% | +40.77% |
| 1 year | +48.51% | +66.73% |
| 3 years | +85.77% | +28.68% |
| Market cap | $665.0B | $1.5B |
| P/E | 41.9 | 39.2 |
| P/S | 6.69 | 1.97 |
| P/B | 8.16 | 2.05 |
| Revenue growth | +7.80% | +3.70% |
| EPS growth | -36.40% | +102.20% |
| Gross margin % | 67.6 | 78.7 |
| Net margin % | 16.2 | 5.1 |
| ROE % | 19.7 | 5.3 |
| Debt / equity | 0.55 | 0.41 |
| FCF yield % | 3.1 | 11.6 |
| Dividend yield % | 1.91 | — |
| Beta | -0.09 | 0.12 |
| RSI (14) | 59.4 | 83.2 |
| Technical rating |